Clinical trial
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT03664960 is registered in ClinicalTrials.gov with Allakos Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
- Lead sponsor
- Allakos Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 14, 2018
- Completion date
- November 2, 2021
- Enrollment
- 58 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
eosinophilic duodenitis, eosinophilic gastritis, eosinophilic gastroenteritis